Entasis Therapeutics Holdings Inc. (ETTX)
$2.19
$0.00 (0.00%)As on 11-Jul-2022 09:30EDT
Market cap
$105 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
6.3
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$-52 Mln
-
ROE
-1.7 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-1.7
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-2
-
Face value
--
-
Shares outstanding
47,851,800
6 Years Aggregate
CFO
$-212.07 Mln
EBITDA
$-226.77 Mln
Net Profit
$-223.46 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Entasis Therapeutics Holdings (ETTX)
| 0.0 | 0.0 | 18.4 | -12.0 | -29.8 | -- | -- |
|
BSE Sensex*
| -12.3 | -4.4 | -3.7 | -10.2 | 3.1 | 4.7 | 10.0 |
|
Company
|
2021
|
2020
|
2019
|
|---|---|---|---|
|
Entasis Therapeutics Holdings (ETTX)
| -11.3 | -50.3 | 22.1 |
|
BSE Sensex
| 22.0 | 15.8 | 14.4 |
|
BSE Sensex
| 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Entasis Therapeutics Holdings (ETTX)
|
2.2 | 104.8 | 0.0 | -86.8 | -- | -300 | -- | 6.3 |
| 12.2 | 744.8 | 0.0 | -175.9 | -- | -106.8 | -- | 5.1 | |
| 13.7 | 2,228.3 | 549.1 | 17.9 | -6.3 | 1.4 | 128.2 | 1.8 | |
| 3.7 | 949.6 | 4.5 | -340.2 | -518.6 | 501.4 | -- | 2.1 | |
| 14.8 | 661.1 | 0.0 | -29.0 | 0.0 | -20.4 | -- | 2.2 | |
| 15.0 | 2,010.2 | 120.8 | -57.8 | -42.4 | -9.9 | -- | 3.5 | |
| 10.6 | 793.4 | 366.5 | 9.3 | 8.3 | 3.4 | 80.1 | 2.8 | |
| 3.1 | 567.7 | 4.1 | -187.9 | -4,613.1 | -233.9 | -- | 0.3 | |
| 12.4 | 809.3 | 0.6 | -60.0 | -9,892.6 | -119 | -- | 21.5 | |
| 25.7 | 2,710.1 | 449.6 | -188.2 | -41.1 | -28.5 | -- | 4.5 |
Shareholding Pattern
View DetailsAbout Entasis Therapeutics Holdings (ETTX)
Entasis Therapeutics Holdings Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibacterial products to treat serious infections caused by multidrug-resistant pathogens in the United... States. Its lead product candidate is sulbactam-durlobactam (SUL-DUR), a novel IV antibiotic that is in Phase III clinical trial for the treatment of pneumonia and bloodstream infections caused by carbapenem-resistant Acinetobacter baumannii. The company also develops Zoliflodacin, a novel orally administered molecule, which is in Phase III clinical trial for the treatment of uncomplicated gonorrhea; ETX0282CPDP, an oral drug that is in Phase I clinical trial for the treatment of urinary tract infections; and ETX0462, a drug candidate from NBP platform that is in pre-clinical stage for the treatment of multidrug-resistant gram-negative infections. The company has a license and collaboration agreement with Zai Lab (Shanghai) Co., Ltd. for the development of durlobactam and SUL-DUR; and collaboration agreement with Global Antibiotic Research and Development Partnership for the development and commercialization of a product candidate zoliflodacin. Entasis Therapeutics Holdings Inc. was founded in 2015 and is headquartered in Waltham, Massachusetts. Entasis Therapeutics Holdings Inc. operates as a subsidiary of Innoviva, Inc. Read more
-
Pres, CEO & Director
Dr. Manoussos Perros Ph.D.
-
Pres, CEO & Director
Dr. Manoussos Perros Ph.D.
-
Headquarters
Waltham, MA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Entasis Therapeutics Holdings (ETTX)
What is the current share price of Entasis Therapeutics Holdings Inc (ETTX) Today?
The share price of Entasis Therapeutics Holdings Inc (ETTX) is $2.19 (NASDAQ) as of 11-Jul-2022 09:30 EDT. Entasis Therapeutics Holdings Inc (ETTX) has given a return of -29.8% in the last 3 years.
What is the current PB & PE ratio of Entasis Therapeutics Holdings Inc (ETTX)?
Since, TTM earnings of Entasis Therapeutics Holdings Inc (ETTX) is negative, P/E ratio is not available.
The P/B ratio of Entasis Therapeutics Holdings Inc (ETTX) is 6.30 times as on 11-Jul-2022, a 78 premium to its peers’ median range of 3.54 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2021 |
-2.00 |
3.02 |
2020 |
-1.17 |
1.13 |
2019 |
-1.47 |
1.53 |
2018 |
-0.37 |
0.15 |
2017 |
-- |
-- |
What is the 52 Week High and Low of Entasis Therapeutics Holdings Inc (ETTX)?
The 52-week high and low of Entasis Therapeutics Holdings Inc (ETTX) are Rs -- and Rs -- as of 19-Sep-2026.
What is the market cap of Entasis Therapeutics Holdings Inc (ETTX)?
Entasis Therapeutics Holdings Inc (ETTX) has a market capitalisation of $ 105 Mln as on 11-Jul-2022. As per SEBI classification, it is a company.
Should I invest in Entasis Therapeutics Holdings Inc (ETTX)?
Before investing in Entasis Therapeutics Holdings Inc (ETTX), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.